Orexigen Therapeutics, Inc. (OREX) Position Boosted by KCG Holdings Inc.

KCG Holdings Inc. boosted its position in shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) by 30.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 43,954 shares of the biopharmaceutical company’s stock after buying an additional 10,139 shares during the period. KCG Holdings Inc. owned about 0.29% of Orexigen Therapeutics worth $151,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Old West Investment Management LLC raised its stake in shares of Orexigen Therapeutics by 0.3% in the first quarter. Old West Investment Management LLC now owns 206,687 shares of the biopharmaceutical company’s stock worth $711,000 after buying an additional 669 shares during the last quarter. Foresite Capital Management II LLC raised its stake in shares of Orexigen Therapeutics by 14.6% in the first quarter. Foresite Capital Management II LLC now owns 622,013 shares of the biopharmaceutical company’s stock worth $2,140,000 after buying an additional 79,258 shares during the last quarter. Foresite Capital Management III LLC raised its stake in shares of Orexigen Therapeutics by 49.7% in the first quarter. Foresite Capital Management III LLC now owns 380,530 shares of the biopharmaceutical company’s stock worth $1,309,000 after buying an additional 126,273 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of Orexigen Therapeutics by 89.1% in the first quarter. Wells Fargo & Company MN now owns 44,538 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 20,988 shares during the last quarter. Hedge funds and other institutional investors own 45.13% of the company’s stock.

Orexigen Therapeutics, Inc. (NASDAQ OREX) opened at 2.42 on Friday. Orexigen Therapeutics, Inc. has a 12 month low of $1.65 and a 12 month high of $5.70. The firm’s market capitalization is $37.34 million. The stock’s 50 day moving average price is $2.59 and its 200-day moving average price is $3.28.

Orexigen Therapeutics (NASDAQ:OREX) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.40) by $0.58. Orexigen Therapeutics had a negative net margin of 120.77% and a negative return on equity of 824.15%. The company had revenue of $23.36 million during the quarter, compared to analyst estimates of $20 million. During the same quarter in the prior year, the business earned ($1.73) earnings per share. The business’s quarterly revenue was up 199.9% compared to the same quarter last year. Equities analysts forecast that Orexigen Therapeutics, Inc. will post ($9.37) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Orexigen Therapeutics, Inc. (OREX) Position Boosted by KCG Holdings Inc.” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.com-unik.info/2017/08/19/kcg-holdings-inc-purchases-10139-shares-of-orexigen-therapeutics-inc-orex-updated.html.

A number of analysts have weighed in on the company. Zacks Investment Research upgraded Orexigen Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 11th. ValuEngine upgraded Orexigen Therapeutics from a “strong sell” rating to a “sell” rating in a report on Tuesday, July 11th.

Orexigen Therapeutics Company Profile

Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.

Institutional Ownership by Quarter for Orexigen Therapeutics (NASDAQ:OREX)

What are top analysts saying about Orexigen Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Orexigen Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit